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Abstract Ontuxizumab (MORAb-004) is a humanized re-
combinant antibody targeting endosialin (TEM-1, CD248).
We conducted an analysis of endosialin expression in meta-
static melanoma specimens using the anti-endosialin rat anti-
MAb 9G5, in order to determine the potential of endosialin as
a therapeutic target within the tumor microenvironment vas-
culature. Endosialin expression in paraffin-embedded archival
tissue block (PEAT) melanoma tissues was assessed using
immunohistochemistry (IHC) with the anti-endosialin, MAb
9G5, in the vessels of American Joint Commission on Cancer
(AJCC) Stage III (n=18) and Stage IV (n=48) specimens.
IHC for endosialin expression was further performed on a
TMA that included 136 Stage IVand 33 paired Stage III mel-
anoma specimens. BRAF mutation (mt) was also evaluated in
individual melanoma specimens and as well as the TMA.
Analysis showed 70 % of melanoma specimens (n=46) were
positive for endosialin expression. There was no significant
difference in endosialin and BRAFmt expression between
stages III vs. IV specimens. Endosialin expression was detect-
ed in 86 % (n=117) of stage IV TMA specimens, while no
expression was detected in 29 normal tissue controls. MAb
9G5 detects the presence of endosialin in the microenviron-
ment tumor vasculature of most metastatic melanoma tissues,
regardless of clinical stage and presence of BRAFmt.
Endosialin may be a potential therapeutic target by virtue of
its selective expression in metastatic melanoma relative to
normal tissues.
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Introduction
Ontuxizumab (MORAb-004) is a humanized recombinant
mouse antibody (Ab) targeting endosialin (TEM-1, CD248)
[1]. The mature form of endosialin is a 175 kDa O-
glycosylated transmembrane protein, with an extracellular re-
gion characterized by the presence of a carbohydrate-binding
lectin like domain and epidermal growth factor (EGF)-like
repeats [2, 3]. Endosialin is predominantly expressed in tumor
blood vessels [4]. High expression of endosialin has been
observed in several solid tumors including colorectal cancer
[5], glioblastoma [6], and breast cancer [7]. In metastatic mel-
anoma, endosialin is selectively expressed in subsets of small-
and medium-sized tumor vessels [8].
Endosialin expression has previously been detected in tu-
mor pericytes and stromal cells by immunohistochemistry
(IHC) [9]. Intratumoral pericytes and stromal cells play an
important role in tumor progression and metastasis. Tumor-
associated fibroblasts in the stroma contribute to migration
and invasion by producing extracellular matrix proteins, ma-
trix metalloproteinases (MMPs) and growth factors [10, 11].
These factors can recruit endothelial precursor cells that initi-
ate angiogenesis. Platelet-derived growth factor-B (PDGF-B),
which is secreted from cancer cells, recruits pericytes that
express PDGF receptor-β (PDGFR-β) on tumor vessels [12,
13]. In endosialin overexpressed transgenic mice, the pericyte
marker, neurite growth proteoglycan 2 (NG2), is co-expressed
with endosialin in tumor vessels but not in CD31-positive
endothelial cells [14]. Thus, endosialin seems to be primarily
expressed on pericytes as opposed to endothelial cells in the
tumor vasculature.
In endosialin-null mice, abdominal implanted tumors have
reduced tumor growth, invasion, and metastasis when com-
pared to wild type mice [15]. Tomkowicz, B., et al. [16] re-
ported that endosialin regulates proliferation of pericytes
through a PDGFR signaling pathway via mitogen-activated
protein (MAP) kinase/extracellular signal-regulated kinase
1/2 (ERK1/2). This data suggests that the suppression of
endosialin in the tumor vasculature may lead to a reduced
number of pericytes, which contributes to the prevention of
tumor progression.
Treatment of aggressive metastatic melanoma has been a
daunting challenge. Several chemotherapies have been uti-
lized for first-line treatment, but very few durable responses
are achieved. Recently, novel molecular-targeted therapies
have been approved by the FDA for first-line treatment in
advanced melanoma i.e., vemurafenib for BRAF V600E mu-
tation (BRAFmt) [17]. However, patients receiving anti-
BRAFmt drugs often experience recurrence and develop ac-
quired resistance within 1 year. Most recently, programmed
cell death protein 1(PD-1) inhibitor has shown significant
clinical activity and has been approved for use in melanoma
patients. Nonetheless, most patients either do not respond or
have a likelihood of recurrence, thus there remains a great
clinical need to identify new drug targets and treatment
strategies.
This study is the first large survey of endosialin protein
expression in clinical melanoma specimens at different dis-
ease stages. Our data shows that endosialin is expressed in
most metastatic melanoma (70-86 %) and not in the normal
tissue, supporting it as a potential new therapeutic target for
advanced stage melanomas. The aim of this study was to
determine endosialin expression in melanomas as a prelude
to in vivo testing and clinical trials, which will eventually
determine the potential of endosialin targeting for patients
with metastatic disease.
A rat MAb anti-endosialin (9G5) was assessed in cutane-
ous melanoma tissue specimens. The MAB 9G5 is very spe-
cific for endosialin/TEM-1/CD248. The MAb specifically
stains the tumor vasculature and stromal regions of the tumor
microenvironment. TEM-1 expression on pericytes and stro-
mal fibroblast of tumor is significantly upregulated and
stained by MAb 9G5. Furthermore, the membranes of
perivascular, normal and non-vascular stroma, as well as tu-
mor and endothelial cells rarely stain for TEM-1.
Materials and Methods
Paraffin-Embedded Archival Tissue
Melanoma patients treated at Saint John’s Health Center be-
tween 1995 and 2011 were reviewed for inclusion in this
study. Approval for the use of human tissues was obtained
from the Saint John’s Health Center/John Wayne Cancer In-
stitute joint institutional review board andWestern institution-
al review board. Informed consent was obtained from all pa-
tients. PEAT (N=66) and frozen tissue (N=16) specimens
were obtained fromAJCC Stage III and IVmelanoma patients
who had either regional lymph node (LN) or distant organ
metastasis. Clinical data was retrieved from the John Wayne
Cancer Institute (JWCI) melanoma database.
Melanoma Tissue Microarray
TMA data was constructed using AJCC stage IV melanomas
from JWCI with annotated clinical outcome as previously
described [18]. The melanoma specimens were derived from
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representative areas of each PEAT block. Cores measuring
0.6 mm in diameter were made for each sample. The AJCC
Stage IV melanoma TMA included 268 distant organ metas-
tases and 39 paired AJCC Stage III regional LN metastases
from 169 melanoma patients, as well as 29 normal tissue con-
trols from each respective organ (cancer-free). Duplicated
cores of all specimens and controls were included in the TMA.
Immunohistochemistry of PEAT and TMA
Immunohistochemistry (IHC) was performed as previously
described using the following reagents and Abs [18]. PEAT
specimens were sectioned at 5 μm and fixed on positively-
charged glass slides. After deparaffinization and rehydration,
the slides were heated for 30 min at 100 °C in Diva heat-
induced epitope retrieval solution (Biocare Medical,
Concorde, CA). Peroxidase-1 blocking solution (Biocare
Medical, Concorde, CA) was applied to specimens and incu-
bated at room temperature for 5min. Tissue sections were then
blocked with 5 % goat serum for 30 min followed by 60 min
incubation at room temperature with 1.25 μg/mL (1:1200 di-
lution) of anti-endosialin clone 9G5 primary rat MAb
(Morphotek, Inc.) diluted in Ab Diluent (Dako, Glostrup,
Denmark). The slides were then incubated for 30 min with
7.5 μg/ml of biotinylated anti-rat secondary link Ab (Vector
Labs, Burlingame, CA) and developed with ABC detection
reagent (Vector Labs, Burlingame, CA) and 3’3’ diaminoben-
zidine (DAB) chromogenic substrate (Dako, Glostrup, Den-
mark). Tissue sections were counterstained with hematoxylin
for 2 min.
IHC of Frozen Tissue
Frozen tissues of AJCC stage III and IV melanoma patients
were prepared with paired PEAT blocks. Frozen tissues were
cryosectioned (5 μm) at −20 °C with Cryocut 1800 (Leica,
Nussloch, Germany) and adhered to slides using CryoJane®
(Instrumedics, Ann Arbor, MI) and adhesive tape window
(Leica Microsystems, Wetzlar, Germany). The tissue on the
tape was transferred to a positively charged slide. After dry-
ing, the slides were stored in a −80 °C freezer for IHC staining.
Prior to the staining procedure, stored slides were air-dried at
room temperature and then fixed in 3 % formaldehyde for
15 min. Following the TBSTwash, the peroxidase-1 blocking
and the remaining consecutive steps were followed as de-
scribed above.
Analysis of Endosialin Expression
IHC staining for endosialin expression in 66 PEAT blocks and
16 frozen specimens was analyzed using ImageJ software
(http://rsbweb.nih.gov/ij). Only vascular regions were
marked by ImageJ and the color was inverted in black and
white mode. Average intensity of endosialin staining for each
marked vascular region was based on the total intensity
divided by the area. The results of endosialin expression
were obtained from the average of two different regions
from each specimen. IHC analysis of endosialin expression
in TMA was scored by a dermatologist (E.K.). After
endosialin staining, specimens without vascular region were
excluded from IHC scoring. Finally, the IHC for endosialin
expression in vascular regions was classified as score 0
(absent), score 1 (weak), score 2 (moderate), and score 3
(strong) by light microscopy as previously described [18].
DNA Extraction
The PEAT blocks for DNA extraction were cut to 10 μm
sections, deparaffinized and stained with hematoxylin. One
5 μm section was cut from each tissue and stained with
hematoxylin and eosin (H&E) to identify tumor region;
thereafter, a 26G needle was used to isolate tumor tissue
for DNA extraction and then subjected to Proteinase K
digestion at 50 °C for 16 h. . ZR FFPE DNA MiniPrepTM
Kit (Zymo Research, Irvine, CA) was then utilized for
DNA extraction in accordance with the manufacturer’s in-
structions. DNA contaminated with melanin was further
purified by OneStep™ PCR Inhibitor Removal Kit (Zymo
Research, Irvine, CA).
Analysis of BRAF V600E Mutation
BRAF (V600E) status for each PEAT specimen was
assessed by TaqMan mutation detection assays competitive
allele-specific PCR (Applied Biosystems, Foster City,
CA). TaqMan PCR were run in 384 wells plate including
5 μl of 2X TaqMan® genotyping master mix (Applied
Biosystems), 0.5 μl of 10X assay mix for allele 1 (or 2),
2.5 μl of deionized water and 2 μl of DNA template
(40 ng) according to the manufacturer’s instruction. PCR
were performed in duplicate on the ABI Prism 7900 HT
sequence detection system (Applied Biosystems) using the
following thermo cycling conditions: 95 °C for 10 min;
5 cycles of 92 °C for 15 s and 58 °C for 1 min; 40 cycles
of 92 °C for 15 s; and 60 °C for 1 min. Collected data were
then analyzed with the SDS 2.0 software program per man-
ufacturer’s instruction. For each run, proper positive and
negative controls were included. BRAFmt of the melano-
ma TMA was stained with monoclonal mouse antibody
VE1 as described previously [19]. Specimens with no tu-
mor, pigmentation or loss of tumor cores were excluded
from IHC scoring. Finally, IHC for BRAFmt detection
was classified as score 0 (negative) or score 1 (positive)
by light microscopy.
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Results
MAb 9G5 Detected Endosialin Expression in Metastatic
Melanomas
To evaluate the specificity and sensitivity of IHC methodolo-
gy in detecting endosialin expression in the tumor microenvi-
ronment vasculature of metastatic melanoma usingMAb 9G5,
we compared endosialin expression in melanoma PEAT spec-
imens with that of two normal tissue types (liver and lung) as
controls (Fig. 1). Endosialin expression was significantly up-
regulated within tumor vessels and stromal region of the mel-
anoma specimens, while none was observed in the vascular
regions of the normal controls. Moreover, as shown in a pre-
vious report, hepatocytes exhibited weak expression of
endosialin, [20].
Correlation of Endosialin Expression with BRAFmt
Approximately 40–60 % of melanoma patient’s tumors re-
portedly harbor the BRAFmt [21, 22]. We analyzed the cor-
relation of endosialin expression with clinical stage and
BRAFmt status of 25 PEAT specimens from AJCC stage III
and IV (8 and 17, respectively). Endosialin expression was
positive in 75 % (n=6) of AJCC Stage III and 41 % (n=7)
of AJCC Stage IV specimens, with an overall expression rate
of 52 % (Table 1a). BRAFmt was detected in 38 % (n=3) of
AJCC Stage III and 35 % (n=6) of AJCC Stage IV melanoma
specimens (Table 1b). Furthermore, endosialin expression
was detected in 33 % (n=3) of BRAFmt positive and 63 %
(n=10) of BRAFmt negative specimens (Table 1c). The ap-
parent trend toward decreased endosialin expression in
BRAFmt positive specimens was not statistically significant;
this trend was reversed in a TMA analysis (see below); there-
fore we detected no consistent correlation of endosialin ex-
pression with BRAFmt status. Endosialin was expressed in
the melanoma vasculature, regardless of BRAFmt.
Endosialin Expression was Similarly Detected in PEAT
and Frozen Melanomas
We analyzed 16 paired PEAT and frozen tissues (AJCC Stage
III and IV) to assess epitope retention, following formalin
fixation (Supplemental Figure 1A). Endosialin expression of
PEAT melanoma was detected in 80 % (n=4) of stage III and
82 % (n=9) of stage IV specimens (Supplemental Table 1A
and Supplemental Figure 1B). Similarly, endosialin expres-
sion of frozen tissues was detected in 80 % (n=4) of stage
III and 73 % (n=8) of stage IV melanoma specimens (Sup-
plemental Table 1B, Supplemental Figure 1C). Consequently,
no significant difference in endosialin expression between
PEAT and frozen metastatic melanoma tissues was observed
(Supplemental Figure 1D), demonstrating the efficiency of













Fig. 1 Representative photos of endosialin expression in melanoma and
normal tissues IHC was performed on normal liver, lung and metastatic
melanoma tissues with MAb 9G5. Normal tissues revealed no endosialin
expression. The vascular regions of metastatic melanoma showed strong
endosialin expression. IgG: negative control staining with isotype Ab and
endosialin: TEM-1 staining with MAb 9G5. Scale bar, 100 μm
Table 1 Endosialin expression associated with BRAFmt
A
Endosialin AJCC Stage III (%) AJCC Stage IV (%) Total (%)
+ 6 (75) 7 (41) 13 (52)
– 2 (25) 10 (59) 12 (48)
Total 8 (100) 17 (100) 25 (100)
B
BRAFmt AJCC Stage III (%) AJCC Stage IV (%) Total (%)
+ 3 (38) 6 (35) 9 (36)
– 5 (72) 11 (65) 16 (64)
Total 8 (100) 17 (100) 25 (100)
C
Endosialin BRAFmt–(%) BRAFmt+(%) Total (%)
+ 10 (63) 3 (33) 13 (52)
– 6 (27) 6 (67) 12 (48)
Total 16 (100) 9 (100) 25 (100)
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Exclusion of Pre-treatment Effect on Endosialin
Expression
There is a possibility that chemotherapy pre-treatment, such as
dacarbazine (DTIC), which patients received before tumor
resection, may have affected endosialin expression. To ex-
clude this possibility, an additional 25 PEAT specimens from
stage III and IV (5 and 20, respectively) patients were ana-
lyzed. This cohort was restricted to patients who did not re-
ceive any treatment 2 months prior to an operation. Endosialin
positive expression was detected in 80 % (n=4) of stage III
and 80 % (n=16) of stage IV specimens (Table 2), similar to
the previous set of PEAT melanoma specimens. Therefore,
these results suggest that chemotherapy pre-treatment did
not affect the level of endosialin expression in the previously
analyzed treated melanoma PEAT specimens.
Comparison in Endosialin Expression Detected
Between Stage III and Stage IV Specimens
All the PEAT melanoma specimens assessed for endosialin
expression with IHC (18 stage III and 48 stage IV melanoma
patients) were compared by stage. 78 % (n=14) of stage III
and 67 % (n=32) of stage IV showed positive expression of
endosialin (Fig. 2 and Table 3). There was no significant dif-
ference in the frequency of endosialin expression between
stage III and IV metastatic melanomas in this cohort. This
suggested that the expression of endosialin is not dependent
on regional or distal disease status (Fig. 3).
TMA Data Analysis
We analyzed endosialin expression in the vasculature of mel-
anoma with a well annotated Stage III and IV melanoma
TMA. We excluded cores that lacked vasculature from the
TMA analysis, resulting in a cohort of 136 Stage IV and 33
paired Stage III melanoma specimens obtained from patients
with metachronous metastases, as well as 29 normal tissue
controls. Endosialin expression with IHC scores of 1, 2 or 3
were detected in 86 % of Stage IV and 82 % of Stage III
melanoma specimens (Table 4) i.e., similar to the data obtain-
ed on examination of whole tumor PEATsections. In addition,
no endosialin expression was detected in the normal tissue
controls. Table 5 shows the metastatic sites for patients, along
with endosialin expression. Gender, ulceration, and metastatic
site showed no correlation with endosialin expression.
BRAFmt status, as previously stated, also showed no signifi-
cant correlation with endosialin expression in the TMA anal-
ysis (Table 6). However, endosialin expression was observed
in 92 % of specimens with the BRAFmt.
Discussion
Angiogenesis is important for tumor growth, invasion and
metastases of cancers. Therefore, treatments targeting angio-
genesis have been used for several cancer types with variable
clinical response [23]. Endosialin may represent an angiogen-
esis related target for melanoma.
Vascular endothelial growth factor (VEGF), which induces
angiogenesis and plays a critical role in the regulation of
vasculogenesis, is an important therapeutic target.[24] Recep-
tor tyrosine kinase (RTK) inhibitors have also been developed,
which block c-KIT and PDGFR [25]. One of the RTK inhib-
itors, Sunitinib, also inhibits VEGFR [25]. Pericytes express-
ing PDGFR and endothelial cells expressing VEGFR are
thought to be the targets of anti-angiogenesis treatments.
While a therapeutic strategy targeting endosialin may also
prove effective, the role of pericyte endosialin in cancer re-
mains unclear. A recent study showed that endosialin on
pericytes binds to the capillary basement membrane and pro-
motes endothelial cell apoptosis [26]. Cell-cell interactions
between pericytes and endothelial cells appear to be required
for vessel stabilization. Taken together, these data suggest that
pericytes play a crucial role in promoting vessel maturation
along with selective vessel destabilization and regression.
Therefore, blocking endosialin function may prevent tumor
vasculature remodeling, whichmay ultimately diminish tumor
blood flow.
The evidence supporting the therapeutic potential of
inhibiting endosialin is conflicting. In support of endosialin
growth enhancing effects, endosialin signaling shares ERK-1/
2 with PDGFR-β signaling to increase pericytes [16]. Inhibi-
tion of PDGFR-β eliminated PDGFR-β+ progenitor
perivascular cells and pericyte quantity [27]. Overexpression
of PDGF-BB (PDGF-B homodimer) in B16F10 melanoma
cells increased the proliferation of pericytes and tumor growth
[28] and overexpression of endosialin enhanced cell migration
in Chinese hamster ovary cells [29]. Growth of colon tumors
implanted in the liver and large intestine was impaired in
endosialin −/− mice [15]. In transgenic mice, deletion of the
cytoplasmic domain of endosialin suppressed tumor growth,
suggesting a role for this domain in signal transduction [30].
Furthermore, elevated endosialin expression (analyzed by an
RT-PCR) in breast tumors has been associated with poor prog-
nosis [7]. Taken together, these studies imply that endosialin
has a role in promoting tumor growth.
Table 2 Endosialin expression in melanoma tissues among patients
without pre-surgery treatment
Endosialin AJCC Stage III (%) AJCC Stage IV (%) Total (%)
+ 4 (80) 16 (80) 20 (80)
– 1 (20) 4 (20) 5 (20)
Total 5 (100) 20 (100) 25 (100)
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Conversely, overexpression of PDGF-BB in colorectal and
pancreatic cancer cell lines suppressed tumor growth and was
associated with increased pericytes in subcutaneous and
orthotopic tumors [31]. In an endosialin KOmodel, tumor size
was not decreased in a subcutaneous colon tumor [15] or
intracranial glioblastoma multiform [32]. Thus, the effect of










Fig. 2 Endosialin expression in
paired PEAT and frozen OCT
melanoma specimens a.
Endosialin IHC staining of
metastatic gallbladder PEAT
specimens and OCT specimens.
IgG: negative control staining
with isotype Ab and endosialin:
Endosialin staining with MAb
9G5. Scale bar, 100 μm. b.
Comparing endosialin expression
levels between stage III and stage
IV PEAT melanoma specimens.
C. Comparing endosialin
expression between stage III and
stage IV OCT frozen melanoma
specimens. d. Comparing
endosialin expression between
PEAT melanoma specimens and
OCT melanoma specimens.
Statistical analysis was conducted
by Fisher’s exact test in B and C.
NS, not significant
Table 3 Endosialin expression of stage III and IV melanomas
Endosialin AJCC Stage III (%) AJCC Stage IV (%) Total (%)
+ 14 (78) 32 (67) 46 (70)
– 4 (22) 16 (23) 20 (30)
Total 18 (100) 48 (100) 66 (100)
Fig. 3 Endosialin expression in AJCC Stage III and IV Melanomas by
IHC analysis Endosialin expression levels for PEATAJCC Stage III and
Stage IV melanoma specimens with MAb 9G5 IHC staining. Statistical
analysis was assessed by Fisher’s exact test. NS, not significant
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followed by clinical trials will be needed to establish
MORAb-004’s therapeutic potential.
While the BRAFmt is the most frequently detected mu-
tation in melanoma, in our study we found no correlation
of the presence of this mutation with endosialin expression,
and endosialin is expressed in 92 % of TMA specimens
with the presence of BRAFmt. Therefore, the presence or
absence of BRAFmt may not influence the clinical re-
sponse to MORAb-004, and this study would not support
patient selection on that basis. However, whether the ex-
pression of endosialin is upregulated in BRAF inhibitor –
resistant melanoma is interesting and remains to be
determined.
In conclusion, we have demonstrated that endosialin can be
recognized by the MAb 9G5 antibody in both PEAT melano-
ma and frozen tissues by IHC analysis. In addition, we
showed that endosialin is highly expressed in the tumor vas-
culature of metastatic melanoma tissues, regardless of clinical
stage and BRAFmt status, and that endosialin is expressed in
most BRAFmt melanomas in a TMA. Although the effect of
inhibiting endosialin function cannot be predicted with cer-
tainty prior to the outcome of human clinical trials, the
findings support further investigation of endosialin as a poten-
tial therapeutic target in melanoma using the MORAb-004
antibody. This study supports further in vivo and clinical in-
vestigations to establish the MORAb-004 antibody’s potential
for melanoma treatment. This study is highly important in that
targeted antigen MAB therapies need a reliable surrogate bio-
marker pathology assay to verify the target antigen present
and level in the tumor or tumor microenvironment as in this
study. More interestingly, endosialin is in the tumor microen-
vironment vasculature where it may be a more effective target
since heterogeneity may be more stable than in the tumor [33].
Both PEATand frozen tissues were shown to be assessable for
anti-endosialin MAB.
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